English
Français
Our advanced gene therapy technology capitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the causes of disease.
Extraordinary progress in developing therapies for CNS diseases with lead programs in neurodegenerative lysosomal storage disorders.
Our team is committed to developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
Our team is committed to fulfilling gene therapy’s potential by developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
News, press releases, and more.
Paris, France — 25 January 2023 at 08:00 am CET —Lysogene (FR0013233475 – LYS), a phase…
Paris, France — 6 January 2023 at 05:00 pm CET —Lysogene (FR0013233475 – LYS), a…
Paris, France — 14 December 2022 at 08:00 am CET — Lysogene (FR0013233475 – LYS),…
Paris, France — 6 December 2022 — Lysogene (FR0013233475 – LYS), a phase 3 gene…
Completion of treatment and 6 months follow-up for the last patient enrolled in Stage 1…
In the cohort of patients enrolled before the age of 30 months, a statistically significant…
Live webcast to be hosted on Wednesday, November 23, 2022 at 1:30 pm CET Paris,…
Cash and cash equivalents of €6.1 million[1] as of 30 September 2022 Paris, France —…
Full data analysis of AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in MPS…
Paris, France —16 September 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS), a…
Valuable information designed to provide knowledge and insights to patients, families, and caregivers.
Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare neurodegenerative lysosomal storage disorder characterized by intractable behavioral problems and developmental regression that typically appears in infancy or early childhood.
GM1 gangliosidosis, or Landing disease, is a rare inherited neurodegenerative lysosomal storage disorder characterized by severe cognitive and motor developmental delays.
Fragile X syndrome (FXS) is the most common inherited cause of autism spectrum disorder and affects approximately 1 in 4,000 to 5,000 boys and 1 in 8,000 girls.
Neuronopathic Gaucher and Parkinson’s disease are both associated with mutations in the GBA1 gene and cause neurological symptoms.
The EURORDIS Company Award for Innovation recognizes Lysogene as a pioneering gene therapy company which has established itself among major players driving European-led innovation, in just over ten years.
